Background: An increasing number of adolescents are seeking gender care at clinics and hospital programs, and requesting gender-affirming hormonal treatment. The interventions can either include suppression of testosterone and introduction of estrogen, or suppression of estrogen and introduction of testosterone.
Aims: This review article focuses on the psychosocial experiences of youth who have completed their endogenous puberty and are now requesting one of these two forms of gender-affirming hormonal treatment. We investigate the comparative profiles of these two subgroups of transgender/gender-expansive youth.
Materials And Methods: Review of research data, established standards of care and practice guidelines, and clinical observations.
Results: Differences and similarities are noted and discussed in several realms: gender-related experiences prior to receiving hormonal treatment; the relationship between the physical changes and psychological experiences that accompany the introduction of testosterone or suppression of testosterone with replacement with estrogen; the intrapersonal and interpersonal implications of the treatment; considerations of fertility preservation for future family building; the role of the family in the decision-making process prior to starting a course of hormone therapy; and the capacity of youth to make informed decisions about these partially irreversible medical interventions.
Discussion: Medical providers who offer gender-affirming hormonal care to youth should work with the family and allied professionals to assure that the youth's gender health is enhanced, barriers to care are removed, and mental health risks are reduced, whether the T is coming out or going in.
Conclusion: The cohort of youth who come to medical providers after completing puberty, and request gender-affirming hormones in the form of increases or reductions in T have a great deal in common, and also extensive variation among them.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/andr.13055 | DOI Listing |
J Sex Med
December 2024
Centre Universitaire d'Enseignement par Simulation-CUESim, Virtual Hospital of Lorraine, Faculty of Medicine, Midwifery and Health Professions, Université de Lorraine, 9, Avenue de la Forêt de Haye, Vandoeuvre-lès-Nancy, 54505, France.
Background: Despite recent evidence of the benefits of gender-affirming medical procedures, data in the literature indicate emerging demands of detransition and regrets while suggesting potential sources of bias in different datasets, including a nonconsensual definition of detransition.
Aim: The present systematic review aims to summarize the existing research regarding the prevalence of detransition in transgender persons who requested or started receiving gonadotrophin-releasing hormone analogs (GnRHa) and/or gender-affirming hormonal therapy (GAHT).
Methods: A systematic literature search (CINAHL Plus, Cochrane Library, Google Scholar, MEDLINE, Web of Science, Sage Journals, Science Direct, Scopus) for quantitative studies was conducted up to May 2024.
J Am Acad Orthop Surg
December 2024
From the University of Michigan Medical School, Ann Arbor, MI (Jacobson), the Department of Physical Medicine and Rehabilitation (Whitney), Department of Orthopedic Surgery (Mamdouhi and Ahn), Consulting for Statistics, Computing and Analytics Research (Janney), and Department of Family Medicine (Blaszczak), University of Michigan, Ann Arbor, MI, and the Department of Orthopaedics, Emory University and Grady Health, Atlanta, GA (Ahn).
Introduction: Gender-affirming hormone therapy (GAHT) is a cornerstone of gender-affirming care for transgender and gender diverse (TGD) patients, with a direct biological role on bone metabolism. However, a paucity of data describes how GAHT influences fracture rate over time. The study's primary objective was to describe the 5-year all-cause fracture incidence rate (IR) among TGD patients initiating estrogen-based GAHT (E-GAHT) or testosterone-based GAHT (T-GAHT), compared with TGD patients not using GAHT (non-GAHT).
View Article and Find Full Text PDFBMC Med Educ
December 2024
Division of Adolescent Medicine, Department of Pediatrics, Seattle Children's Hospital, Seattle, WA, USA.
Purpose: Healthcare providers often lack training and education in caring for gender diverse youth. We aimed to explore changes in provider confidence and behaviors following the implementation of an online learning course focused on gender affirming care for youth.
Methods: An asynchronous, online training consisting of 2 modules was made available in October 2021.
Ther Adv Endocrinol Metab
December 2024
Trans Health Research Group, Department of Medicine, University of Melbourne, Parkville, VIC 3052, Australia.
Background: There is interest in repurposing bicalutamide for gender-affirming hormone therapy, but little data regarding efficacy and safety in the transgender population.
Objectives: To determine the effect of bicalutamide on serum total testosterone concentrations and liver function. Given bicalutamide is a pure androgen receptor antagonist, we hypothesized that serum total testosterone concentrations would be higher than the cisgender female reference range and those recommended for transgender individuals in consensus guidelines.
Open Forum Infect Dis
December 2024
Institute of Human Virology at the University of Maryland Baltimore, Baltimore, Maryland, USA.
Background: Transgender people assigned male at birth (TG-AMAB) have higher rates of anal human papillomavirus (HPV) infection and anal cancer compared with cisgender populations. In a cohort of TG-AMAB in Washington DC, we determined the prevalence and epidemiological factors associated with anal high-risk HPV (HR-HPV) infection and cytological abnormalities.
Methods: In an urban academic-community clinic, we recruited adults identifying as a gender different than their sex assigned at birth.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!